ADMA Biologics Announces First Commercial Sales of ASCENIV™
see the press release
ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us, and our hands-on approach to production and development that sets us apart.
ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™
ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™:READ MOREADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock
ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock:READ MOREADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock
ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock:READ MORE